Published in Cancer Lett on August 13, 2007
Use of bisphosphonates and reduced risk of colorectal cancer. J Clin Oncol (2011) 1.84
Lipophilic bisphosphonates as dual farnesyl/geranylgeranyl diphosphate synthase inhibitors: an X-ray and NMR investigation. J Am Chem Soc (2009) 1.75
Tumour macrophages as potential targets of bisphosphonates. J Transl Med (2011) 1.53
Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. J Cell Mol Med (2010) 1.52
Activating and propagating polyclonal gamma delta T cells with broad specificity for malignancies. Clin Cancer Res (2014) 1.32
Metastasis and bone loss: advancing treatment and prevention. Cancer Treat Rev (2010) 1.32
Allosteric non-bisphosphonate FPPS inhibitors identified by fragment-based discovery. Nat Chem Biol (2010) 1.30
Cancer treatment dosing regimens of zoledronic acid result in near-complete suppression of mandible intracortical bone remodeling in beagle dogs. J Bone Miner Res (2010) 1.25
Bispecific T-cells expressing polyclonal repertoire of endogenous γδ T-cell receptors and introduced CD19-specific chimeric antigen receptor. Mol Ther (2013) 1.09
How do bisphosphonates inhibit bone metastasis in vivo? Neoplasia (2010) 1.03
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs. Chem Rev (2016) 1.02
Farnesyl diphosphate synthase inhibitors from in silico screening. Chem Biol Drug Des (2013) 1.02
Gammadelta T-cells: potential regulators of the post-burn inflammatory response. Burns (2008) 1.01
Zoledronic acid restores doxorubicin chemosensitivity and immunogenic cell death in multidrug-resistant human cancer cells. PLoS One (2013) 0.98
The Impact of Microenvironmental Heterogeneity on the Evolution of Drug Resistance in Cancer Cells. Cancer Inform (2015) 0.94
Enhancement of subchondral bone quality by alendronate administration for the reduction of cartilage degeneration in the early phase of experimental osteoarthritis. Clin Exp Med (2011) 0.88
Bone structural components regulating sites of tumor metastasis. Curr Osteoporos Rep (2011) 0.88
In vitro and in vivo antiplasmodial activities of risedronate and its interference with protein prenylation in Plasmodium falciparum. Antimicrob Agents Chemother (2011) 0.86
Enhanced anti-tumor effect of zoledronic acid combined with temozolomide against human malignant glioma cell expressing O6-methylguanine DNA methyltransferase. PLoS One (2014) 0.86
Zoledronic acid induces formation of a pro-apoptotic ATP analogue and isopentenyl pyrophosphate in osteoclasts in vivo and in MCF-7 cells in vitro. Br J Pharmacol (2009) 0.85
Bisphosphonate use and risk of colorectal cancer: a systematic review and meta-analysis. Br J Clin Pharmacol (2013) 0.84
New symmetrically esterified m-bromobenzyl non-aminobisphosphonates inhibited breast cancer growth and metastases. PLoS One (2009) 0.84
An osteoclast-targeting agent for imaging and therapy of bone metastasis. Bioorg Med Chem Lett (2008) 0.83
Analysis of molecular mechanisms and anti-tumoural effects of zoledronic acid in breast cancer cells. J Cell Mol Med (2012) 0.82
Synergistic suppression of human breast cancer cells by combination of plumbagin and zoledronic acid In vitro. Acta Pharmacol Sin (2015) 0.78
In silico investigations of the anti-catabolic effects of pamidronate and denosumab on multiple myeloma-induced bone disease. PLoS One (2012) 0.77
Human farnesyl pyrophosphate synthase inhibition by nitrogen bisphosphonates: a 3D-QSAR study. J Comput Aided Mol Des (2013) 0.76
Bone Targeted Therapies for Bone Metastasis in Breast Cancer. J Clin Med (2013) 0.76
Bone-targeted therapy in metastatic breast cancer - all well-established knowledge? Breast Care (Basel) (2014) 0.75
Design and Biological Evaluation of Delivery Systems Containing Bisphosphonates. Pharmaceutics (2016) 0.75
Three-Dimensional Mechanical Loading Modulates the Osteogenic Response of Mesenchymal Stem Cells to Tumor-Derived Soluble Signals. Tissue Eng Part A (2016) 0.75
Geranylgeranyl diphosphate synthase inhibition induces apoptosis that is dependent upon GGPP depletion, ERK phosphorylation and caspase activation. Cell Death Dis (2017) 0.75
Intra-tumor delivery of zoledronate mitigates metastasis-induced osteolysis superior to systemic administration. J Bone Oncol (2017) 0.75
Are macrophages in tumors good targets for novel therapeutic approaches? Mol Cells (2014) 0.75
Inhibition of the mevalonate pathway augments the activity of pitavastatin against ovarian cancer cells. Sci Rep (2017) 0.75
Effects of high dose of zoledronic acid on superficial vascular network of membranous bone sites: an intravital study on rat calvarium. Osteoporos Int (2009) 0.75
The miR-21/PTEN/Akt signaling pathway is involved in the anti-tumoral effects of zoledronic acid in human breast cancer cell lines. Naunyn Schmiedebergs Arch Pharmacol (2016) 0.75
Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human γδ T-cell subset. Blood (2012) 2.57
Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J Clin Invest (2004) 2.30
Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res (2002) 1.97
Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst (2008) 1.87
Integrin alpha(v)beta3 expression confers on tumor cells a greater propensity to metastasize to bone. FASEB J (2002) 1.64
Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer. Cancer Res (2007) 1.63
The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases. Proc Natl Acad Sci U S A (2006) 1.61
Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J Natl Cancer Inst (2007) 1.56
Tumor alphavbeta3 integrin is a therapeutic target for breast cancer bone metastases. Cancer Res (2007) 1.55
SiRNA-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin-1 and slows tumor vascularization and growth. Cancer Res (2003) 1.55
Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. J Cell Mol Med (2010) 1.52
Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP. Br J Haematol (2008) 1.51
Direct and indirect anticancer activity of bisphosphonates: a brief review of published literature. Cancer Treat Rev (2011) 1.34
High phosphoantigen levels in bisphosphonate-treated human breast tumors promote Vgamma9Vdelta2 T-cell chemotaxis and cytotoxicity in vivo. Cancer Res (2011) 1.34
Metastasis and bone loss: advancing treatment and prevention. Cancer Treat Rev (2010) 1.32
The HIF-1-inducible lysyl oxidase activates HIF-1 via the Akt pathway in a positive regulation loop and synergizes with HIF-1 in promoting tumor cell growth. Cancer Res (2011) 1.17
Increased expression and serum levels of the stromal cell-secreted protein periostin in breast cancer bone metastases. Int J Cancer (2010) 1.16
A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden. Cancer Res (2007) 1.15
Mechanisms of bisphosphonate effects on osteoclasts, tumor cell growth, and metastasis. Am J Clin Oncol (2002) 1.15
Cancer cell expression of autotaxin controls bone metastasis formation in mouse through lysophosphatidic acid-dependent activation of osteoclasts. PLoS One (2010) 1.12
Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo. Clin Cancer Res (2008) 1.10
Androgens repress the expression of the angiogenesis inhibitor thrombospondin-1 in normal and neoplastic prostate. Cancer Res (2005) 1.10
Cathepsin K inhibitors as treatment of bone metastasis. Curr Opin Support Palliat Care (2008) 1.07
How do bisphosphonates inhibit bone metastasis in vivo? Neoplasia (2010) 1.03
Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase. Bone (2010) 1.01
Platelet is a major contributor to circulating levels of Dickkopf-1: clinical implications in patients with multiple myeloma. Br J Haematol (2009) 1.01
Dual function of ERRα in breast cancer and bone metastasis formation: implication of VEGF and osteoprotegerin. Cancer Res (2011) 1.00
Activation of γδ T cells by bisphosphonates. Adv Exp Med Biol (2010) 0.99
Aminobisphosphonate-pretreated dendritic cells trigger successful Vgamma9Vdelta2 T cell amplification for immunotherapy in advanced cancer patients. Cancer Immunol Immunother (2010) 0.97
In vitro comparison of clodronate, pamidronate and zoledronic acid effects on rat osteoclasts and human stem cell-derived osteoblasts. Basic Clin Pharmacol Toxicol (2005) 0.95
Human breast tumors override the antiangiogenic effect of stromal thrombospondin-1 in vivo. Int J Cancer (2005) 0.95
Lowering bone mineral affinity of bisphosphonates as a therapeutic strategy to optimize skeletal tumor growth inhibition in vivo. Cancer Res (2008) 0.94
In vivo phosphoantigen levels in bisphosphonate-treated human breast tumors trigger Vγ9Vδ2 T-cell antitumor cytotoxicity through ICAM-1 engagement. Clin Cancer Res (2012) 0.93
Mevalonate pathway intermediates downregulate zoledronic acid-induced isopentenyl pyrophosphate and ATP analog formation in human breast cancer cells. Biochem Pharmacol (2009) 0.92
The molecular basis of bisphosphonate activity: a preclinical perspective. Semin Oncol (2010) 0.90
Transmigration: a new property of mature multinucleated osteoclasts. J Bone Miner Res (2006) 0.89
TWIST1 expression in breast cancer cells facilitates bone metastasis formation. J Bone Miner Res (2014) 0.88
Bioactive lipids lysophosphatidic acid and sphingosine 1-phosphate mediate breast cancer cell biological functions through distinct mechanisms. Oncol Res (2009) 0.87
Analysis of endogenous ATP analogs and mevalonate pathway metabolites in cancer cell cultures using liquid chromatography-electrospray ionization mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2009) 0.87
Zoledronic acid induces formation of a pro-apoptotic ATP analogue and isopentenyl pyrophosphate in osteoclasts in vivo and in MCF-7 cells in vitro. Br J Pharmacol (2009) 0.85
Nephrogenic systemic fibrosis-like effects of magnetic resonance imaging contrast agents in rats with adenine-induced renal failure. Toxicol Sci (2012) 0.85
Targeting lysophosphatidic acid receptor type 1 with Debio 0719 inhibits spontaneous metastasis dissemination of breast cancer cells independently of cell proliferation and angiogenesis. Int J Oncol (2011) 0.85
A new murine model of osteoblastic/osteolytic lesions from human androgen-resistant prostate cancer. PLoS One (2013) 0.83
Differential proteomic analysis of a human breast tumor and its matched bone metastasis identifies cell membrane and extracellular proteins associated with bone metastasis. J Proteome Res (2012) 0.82
Cell membrane proteomic analysis identifies proteins differentially expressed in osteotropic human breast cancer cells. Neoplasia (2008) 0.82
A convenient clinically relevant model of human breast cancer bone metastasis. Clin Exp Metastasis (2007) 0.81
Correlation between time-dependent inhibition of human farnesyl pyrophosphate synthase and blockade of mevalonate pathway by nitrogen-containing bisphosphonates in cultured cells. Biochem Biophys Res Commun (2011) 0.80
Lysophosphatidic acid receptor type 1 (LPA1) plays a functional role in osteoclast differentiation and bone resorption activity. J Biol Chem (2014) 0.79
Combination of anti-angiogenic therapies reduces osteolysis and tumor burden in experimental breast cancer bone metastasis. Int J Cancer (2014) 0.79
Development of a new ELISA for serum periostin: evaluation of growth-related changes and bisphosphonate treatment in mice. Calcif Tissue Int (2010) 0.78
[Does tumor angiogenesis play a role in bone metastatic process?]. Rev Med Suisse Romande (2004) 0.77
Nanostructured polyelectrolyte multilayer drug delivery systems for bone metastasis prevention. Biomaterials (2009) 0.76
[Lysophosphatidic acid: a new link between blood platelets and bone metastasis]. Med Sci (Paris) (2005) 0.76
Frequent low-dose bisphosphonate therapy. Bone (2007) 0.75
Molecularly targeted therapies in breast cancer bone metastases. Curr Pharm Des (2010) 0.75